Physician profile
Gerald A Ngo
NPI 1326427220
$5,910.05
in general payments reported to CMS, 2019-2025
27 companies · $943 in 2025
The $943 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $585 · 2020: $401 · 2021: $546 · 2022: $1,106 · 2023: $854 · 2024: $1,474 · 2025: $943.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,878 · Consulting Fee: $1,114 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $168 · Honoraria: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,878.39 |
| Consulting Fee | $1,114.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $168.00 |
| Honoraria | $111.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,912.86 | 2022-2025 | Trailblazer, Nitrex, Minimed 780g |
| Abbott Laboratories | $695.86 | 2021-2025 | Gallant, Freestyle Libre, Tendril |
| Novartis Pharmaceuticals Corporation | $519.60 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $432.41 | 2021-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $399.25 | 2019-2023 | Xarelto |
| Astellas Pharma US INC | $274.94 | 2020-2021 | |
| Pfizer INC. | $258.12 | 2020-2025 | |
| Becton, Dickinson and Company | $226.00 | 2024-2025 | Site-Rite, Powerpicc, Introducer Needle |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.49 | 2019-2022 | |
| Heartflow, INC. | $169.11 | 2024 | |
| Lilly USA, LLC | $151.31 | 2021-2024 | Mounjaro, Zepbound |
| Dexcom, INC. | $131.35 | 2022-2023 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $105.40 | 2021-2022 | |
| Novo Nordisk INC | $101.30 | 2022 | |
| Amgen INC. | $56.15 | 2019-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| C. R. Bard, INC. & Subsidiaries | $53.00 | 2024 | |
| Insulet Corporation | $41.74 | 2023-2025 | Omnipod |
| Amarin Pharma, INC. | $29.34 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $27.30 | 2019 | |
| Abiomed | $22.50 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.09 | 2023 | Lifevest |
| Baxter Healthcare | $18.94 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Octapharma USA, INC. | $14.90 | 2025 | Fibryga |
| Kowa Pharmaceuticals America, INC. | $14.78 | 2021 | |
| Azurity Pharmaceuticals, INC. | $14.49 | 2024 | Edarbi |
| Medivance, INC. | $14.14 | 2020 | |
| Cvrx, INC. | $11.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Ngo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.